Analyze the Cardiovascular Benefits of the Different GLP-1 Agonists
Dulaglutide (Trulicity) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.
It joins semaglutide (Ozempic) and liraglutide (Victoza). All three lower CV risk in type 2 patients with CV disease or at high CV risk.
Each of these meds also seems to slow progression to albuminuria...but none have been shown to delay dialysis.